Table 4.
Direct comparison between study cohort and historical cohort of HB in the Netherlands.
| All Liver Tumours n = 26 (%) |
HB n = 14 (%) |
HB Historical Group n = 94 (%) |
p Value | |
|---|---|---|---|---|
| Complication percentage | 9 (35) | 4 (29) | 42/73 (54) | 0.0774 |
| Haemorrhage | 3 (12) | 1 (7) | 33/73 (45) | 0.0071 * |
| Biliary | 0 (0) | 0 (0) | 9/73 (13) | 0.344 |
| Vascular | 0 (0) | 0 (0) | 2/73 (3) | 1.0 |
| Infection | 4 (15) | 3 (21) | 6/73 (8) | 0.1548 |
| Other | 7 (27) | 3 (21) | NA | |
| Recurrent disease | 2 HCC, 1 CNSET AWD (12%) | 0 (0) | Total 16/94, liver 3/94, pulmonary 12/94, both 1 (17) | 0.1199 |
| OLT | 7 (27) | 14 (2) | 18/94 (19) | 1 |
| Survival 30 d. | 100 (nr at risk 26) | 100 (nr at risk 14) | 100 | |
| Survival 90 d. | 100 (nr at risk 26) | 100 (nr at risk 14) | NA | |
| Survival 1 jr. | 100 (nr at risk 25) | 100 (nr at risk 14) | NA | |
| Survival 5 jr. | 92 (nr at risk 4) | 100 (nr at risk 2) | 82 (77/94) | 0.1199 |
* p value of <0.05 is considered statistically significant in the Fisher’s exact test.